Allele a of the rs16147 variant of neuropeptide Y predicts early metabolic improvements after bariatric surgery with biliopancreatic diversion in morbid obese subjects

Abstract

Clinical Nutrition Open Science 36 (2021) 26e34 mUI/L vs. À1.7 ± 0.2 mUI/L; p ¼ 0.03), year two (delta: -1.1 ± 0.2 mUI/L vs. À1.8 ± 0.2 mUI/L; p ¼ 0.02), too. Conclusion:The presence of A allele of rs16147 genetic variant produces an early metabolic response secondary to weight loss after bariatric surgery.

Genetic variants associated with weight loss and metabolic outcomes after bariatric surgery: A systematic review

“…Follow‐up ranged from 6 months to 7 years. Weight loss was expressed as change in BMI in 11 studies, 25–34 percentage excess BMI loss (EBMIL) in one study, 35 percentage TWL in nine studies, 36–44 and excess weight loss (EWL) in 29 studies 45–73 . Patients underwent various types of bariatric procedures including RYGB, SG, and LAGB.…”

“…For numerous genes, only one or more SNPs were examined, and no significant association was found between the genetic variant and weight loss after bariatric surgery 33,36,40,42,46,47,54,58,63,67,68,73 …”

“…Follow‐up ranged from 6 months to 5 years. Changes in frequency of obesity‐related metabolic problems were reported in 18 studies, 32,40,47–60,68,72 and fasting glucose, HOMA IR, HbA1c, and/or lipids were reported in 21 studies 27,29,47–60,68,69,74–76 . One study used diabetes remission, defined as cessation of antidiabetic therapies, as outcome 34 .…”

“…For polymorphisms of 17 genes, the association between SNPs with postoperative metabolic improvement was only examined in one study. Neuropeptide Y ( NPY ) (rs16147), brain‐derived neurotrophic factor ( BDNF ) (rs10767664), apolipoprotein A1 ( APOA1 ) (rs670), and cannabinoid receptor 2 ( CB2R ) (rs3123554) variants were associated with increased improvement in glucose homeostasis including fasting glucose, fasting insulin, and HOMA IR after BPD 53,54,57,68 . Human catalase gene promotor haplotype ( CAT ) (rs769214) was associated with lower CRP and diastolic blood pressure levels 12 months after RYGB, LAGB, and SG 74 .…”

Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk

“…Another interesting SNP site was identified in NPY (Neuropeptide Y), which is a six-amino-acid peptide neurotransmitter, expressed by chromaffin and noradrenergic cells. It was suggested that high NPY expression in the hypothalamus is related to the development of T2DM, IR, and obesity [ 181 ]. Probably, the rs16147 variant has altered interaction properties with transcription factor and other regulatory elements.…”